Matinas Biopharma Holdings Inc (MTNB)

[The Lawman]

MAT 9001 Beat Vascepa In Head to Head Trial.

While MAT 9001, Matinas Biopharma's (MTNB) omega drug, handily bested Vascepa in a head to head trial, the market cap of MTNB is a tiny fraction of that of Amarin (AMRN).

That would make no sense even if MAT 9001 was MTNB's only drug.

However, MAT 9001 is a secondary drug in MTNB's portfolio.

MTNB's primary drug is a lipid nano crystal (LNC) drug delivery system that allows for efficacious but highly toxic drugs to be administered without any toxicity.

The NIH has invested over $15M in MTNB's LNC drug delivery system, and is continuing to fund additional trials at this time.

Thus, MTNB has two very valuable franchises; omega and LNC.

Given the great potential of these two drug franchises, it is surprising the market cap of MTNB is a tiny fraction of AMRN which has only an omega drug that, while paving the way for MAT 9001, is likely to eventually be supplanted by it.

LM